Paid Clinical Trials and Focus Groups by Location |
|
|
|
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Linagliptin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Not yet recruiting - verified September 2010
Conditions: HIV Infection; Mitochondrial Dysfunction
Interventions: Drug: Atazanavir/ritonavir; Drug: Efavirenz
Sponsors: The Cleveland Clinic; National Institute of Allergy and Infectious Diseases (NIAID); Case Western Reserve University; Bristol-Myers Squibb
Not yet recruiting - verified September 2010
Condition: Acute Gout
Intervention: Drug: ACZ885
Sponsor: Novartis Pharmaceuticals
Recruiting - verified September 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: placebo; Drug: placebo; Drug: Disease-modifying antirheumatic drugs (DMARDs)
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified September 2010
Conditions: Cystic Fibrosis With Mild to Moderate Lung Disease; CMRI of Lung Perfusion; Lung Perfusion; Lung Vascularization
Intervention: Drug: Sildenafil
Sponsor: Children's Hospital Medical Center, Cincinnati
Not yet recruiting - verified September 2010
Conditions: Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Infant, Newborn; Hypoxia, Brain; Hypoxia-Ischemia, Brain; Encephalopathy, Hypoxic-Ischemic; Hypoxic-Ischemic Encephalopathy; Ischemic-Hypoxic Encephalopathy
Intervention: Procedure: Whole-body Cooling
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Not yet recruiting - verified July 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine; Drug: insulin aspart
Sponsor: Novo Nordisk
Not yet recruiting - verified August 2010
Conditions: Infant, Newborn; Infant, Small for Gestational Age; Infant, Very Low Birth Weight; Infant, Premature; Intracranial Hemorrhages
Interventions: Drug: Vitamin E; Drug: Placebo
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Not yet recruiting - verified July 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Not yet recruiting - verified August 2010
Conditions: Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions: Drug: erlotinib hydrochloride; Radiation: intensity-modulated radiation therapy; Other: pharmacogenomic studies; Other: gene expression analysis; Radiation: 3-dimensional conformal radiation therapy; Other: biopsy; Other: pharmacological study; Other: laboratory biomarker analysis; Other: questionnaire administration; Other: enzyme-linked immunosorbent assay; Other: polymorphism analysis
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Not yet recruiting - verified August 2010
Conditions: Oral Squamous Cell Carcinoma; Oral Epithelial Dysplasia
Interventions: Drug: Bioadhesive 10% freeze-dried black raspberry gel; Drug: Color/consistency matched placebo gel
Sponsors: Ohio State University; University of Louisville; University of North Carolina, Chapel Hill; National Cancer Institute (NCI)
Not yet recruiting - verified August 2010
Condition: Congenital Heart Disease
Intervention: Other: Blood Sample Collection
Sponsor: Nationwide Children's Hospital
Recruiting - verified August 2010
Conditions: Breastfeeding; Lactation; Analgesia
Intervention:
Sponsor: MetroHealth Medical Center
Not yet recruiting - verified August 2010
Condition: Hemorrhage
Interventions: Biological: secondary hemostatic treatment; Device: Surgicel® Original
Sponsor: Nycomed
Not yet recruiting - verified August 2010
Conditions: Hyperphosphatemia; High Phosphorus; Dialysis; Kidney Failure
Intervention: Drug: ferric citrate, calcium acetate, sevelamer carbonate, placebo
Sponsor: Keryx Biopharmaceuticals
Not yet recruiting - verified September 2010
Conditions: Primary Dystonia; Epilepsy; Hydrocephalus; Bladder Control; Deaf or Hearing Impaired
Intervention:
Sponsor: Food and Drug Administration (FDA)
Recruiting - verified August 2010
Condition: Keratoconus
Intervention: Other: The VEGA UV-A Illumination System
Sponsor: Topcon Medical Systems, Inc.
Recruiting - verified August 2010
Condition: High Grade Glioma
Intervention: Other: 3T MRI
Sponsor: University of Cincinnati
Recruiting - verified August 2010
Condition: Thrombocytopenia
Intervention: Drug: Eltrombopag
Sponsors: University of Cincinnati; GlaxoSmithKline
Recruiting - verified August 2010
Condition: Myringotomy and Placement of PE (Pressure Equalization) Tubes
Interventions: Drug: Dexmedetomidine; Drug: Fentanyl
Sponsor: Nationwide Children's Hospital
Not yet recruiting - verified August 2010
Condition: Partial Onset Epilepsy
Interventions: Drug: Lacosamide; Drug: Placebo
Sponsors: The Cleveland Clinic; UCB, Inc.
Recruiting - verified August 2010
Conditions: Obstructive Sleep Apnea; Obesity
Interventions: Device: CPAP; Procedure: Laparoscopic Gastric Banding
Sponsors: Case Western Reserve University; National Heart, Lung, and Blood Institute (NHLBI); Brigham and Women's Hospital
Not yet recruiting - verified August 2010
Condition: Restless Legs Syndrome
Interventions: Drug: rasagiline; Drug: placebo (sugar pill)
Sponsors: University of Virginia; Teva Neuroscience, Inc.
Not yet recruiting - verified August 2010
Conditions: SCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis; ADA Deficiency; XSCID
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); NIH Office of Rare Diseases Research
Recruiting - verified August 2010
Conditions: Lymphoblastic Leukemia, Acute; Lymphoblastic Leukemia, Acute, Childhood; Leukemia, Lymphoblastic, Acute, T Cell; Leukemia, Lymphoblastic, Acute
Interventions: Drug: EZN-3042; Drug: Cytarabine; Drug: Doxorubicin; Drug: Prednisone; Drug: Vincristine; Drug: Pegaspargase; Drug: Methotrexate
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Enzon Pharmaceuticals, Inc.
Recruiting - verified August 2010
Conditions: Hyperglycemia; Coronary Artery Bypass Graft; Coronary Artery Bypass
Interventions: Other: HNC; Other: control group
Sponsors: Outcomes Research Consortium; National Institutes of Health (NIH)
Recruiting - verified August 2010
Condition: Transesophageal Transducer
Intervention: Device: PET-512MC
Sponsor: Toshiba America Medical Systems, Inc.
Recruiting - verified August 2010
Condition: Arthritis, Rheumatoid
Interventions: Drug: LY3009104; Drug: Placebo
Sponsors: Eli Lilly and Company; Incyte Corporation
Not yet recruiting - verified August 2010
Conditions: Colonoscopy; Endoscopy
Interventions: Other: PillCam® COLON 2 procedure using MgC boosts; Other: PillCam® COLON 2 procedure using Moviprep boosts
Sponsor: Given Imaging Ltd.
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Alpha 1-Antitrypsin (AAT, Aralast NP)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network; Juvenile Diabetes Research Foundation
Not yet recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Alpha 1-Antitrypsin (AAT, Aralast NP); Drug: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network; Juvenile Diabetes Research Foundation
Not yet recruiting - verified August 2010
Conditions: Brain Stem Neoplasms; Glioma; Pinealoma
Interventions: Drug: IMC-A12; Drug: Temsirolimus
Sponsor: National Cancer Institute (NCI)
Recruiting - verified July 2010
Condition: Revision, Joint
Interventions: Device: Zimmer Trabecular Metal Revision Cup; Device: Zimmer Modular Cup
Sponsors: The Cleveland Clinic; Zimmer, Inc.
Recruiting - verified August 2010
Condition: Contraception
Interventions: Drug: Contraception; Drug: Contraception
Sponsor: Agile Therapeutics
Recruiting - verified August 2010
Condition: Influenza
Interventions: Biological: Inactivated Trivalent Influenza Vaccine; Drug: Placebo (IN); Biological: Live Attenuated Influenza Vaccine; Drug: Placebo (IM)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified August 2010
Conditions: Chronic Kidney Disease; Obesity
Interventions: Behavioral: Diet and exercise; Procedure: Bariatric Surgery
Sponsor: The Cleveland Clinic
Recruiting - verified August 2010
Condition: Cystic Fibrosis
Interventions: Drug: MP-376 (Levofloxacin solution for Inhalation); Drug: Placebo
Sponsor: Mpex Pharmaceuticals
Not yet recruiting - verified August 2010
Condition: Lung Cancer
Interventions: Other: General-epidural anesthesia and analgesia; Other: Balanced general anesthesia and postoperative opioids
Sponsor: Outcomes Research Consortium
Recruiting - verified August 2010
Conditions: Alcohol Dependence; Nicotine Dependence
Interventions: Drug: Topiramate with brief behavioral enhancement therapy; Drug: Placebo plus brief behavioral enhancement therapy
Sponsors: University of Virginia; National Institute on Alcohol Abuse and Alcoholism (NIAAA); University of Houston; University of Cincinnati; M.D. Anderson Cancer Center
Not yet recruiting - verified August 2010
Conditions: Ischemic Heart Disease; Coronary Artery Stenosis; Chronic Coronary Total Occlusion; Coronary Bypass Graft Stenosis
Intervention: Device: MINI TREK RX 1.20 mm Coronary Dilatation Catheter
Sponsor: Abbott Vascular
Not yet recruiting - verified August 2010
Condition: Depressive Disorder, Major
Interventions: Drug: LuAA21004; Drug: LuAA21004; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo
Sponsor: Novo Nordisk
Recruiting - verified September 2010
Conditions: Contraception; Female Contraception
Intervention: Drug: DR-102
Sponsor: Teva Women's Health
Recruiting - verified September 2010
Condition: Rhinovirus
Interventions: Drug: BTA798; Drug: Placebo
Sponsor: Biota Scientific Management Pty Ltd
Recruiting - verified August 2010
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: 50mg Nilotinib; Drug: 150mg Nilotinib; Drug: 300mg Nilotinib; Drug: Nilotinib Placebo
Sponsor: Novartis
Recruiting - verified August 2010
Conditions: Orthostatic Hypotension; Parkinson's Disease
Intervention: Drug: Droxidopa
Sponsor: Chelsea Therapeutics
Recruiting - verified August 2010
Conditions: Low Back Pain; Radiating Pain
Interventions: Other: Entonox; Other: Oxygen
Sponsor: Outcomes Research Consortium
Recruiting - verified July 2010
Condition: Asthma
Interventions: Drug: 50 mcg salmeterol HFA MDI; Drug: placebo; Drug: 5 mcg tiotropium Respimat®; Drug: 2.5 mcg tiotropium Respimat®
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified August 2010
Condition: Anesthesia
Intervention: Other: No Intervention Used
Sponsor: University Hospital Case Medical Center
Not yet recruiting - verified July 2010
Condition: Soft Tissue Sarcoma
Interventions: Drug: doxorubicin in combination with palifosfamide-tris; Drug: doxorubicin in combination with placebo
Sponsor: ZIOPHARM
Recruiting - verified August 2010
Conditions: Keratoconus; Ectasia; Degeneration
Interventions: Drug: Ciprofloxicine or Vigamox or other.; Drug: Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc); Drug: Steroid (FML, Pred Forte, Flarex, etc.)
Sponsor: Innovative Medical
Recruiting - verified September 2010
Condition: Pediatric Mania
Interventions: Drug: Lithium Carbonate; Drug: Placebo
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified July 2010
Condition: Primary Immune Deficiency
Intervention: Biological: Subcutaneous IgG (SCIG)
Sponsor: CSL Behring
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: insulin aspart; Drug: insulin detemir; Drug: insulin aspart; Drug: insulin detemir
Sponsor: Novo Nordisk
Not yet recruiting - verified August 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Docetaxel; Biological: Ramucirumab; Drug: Placebo
Sponsors: Eli Lilly and Company; ImClone LLC
Not yet recruiting - verified August 2010
Condition: Hypertension, Pulmonary
Interventions: Drug: ambrisentan; Drug: tadalafil
Sponsors: GlaxoSmithKline; Gilead Sciences
Not yet recruiting - verified August 2010
Condition: Asthma
Interventions: Drug: Vilanterol; Drug: Salmeterol Inhalation Powder; Drug: Placebo Inhalation Powder NDPI; Drug: Placebo Inhalation Powder Diskus
Sponsor: GlaxoSmithKline
Not yet recruiting - verified August 2010
Condition: Influenza
Intervention: Biological: Trivalent Inactivated Influenza Vaccine
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified July 2010
Conditions: Herpes Zoster; Herpes Zoster Vaccine
Interventions: Biological: Herpes Zoster Vaccine GSK1437173A; Biological: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified August 2010
Condition: Herpes Zoster
Interventions: Biological: Herpes Zoster Vaccine GSK1437173A; Biological: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified August 2010
Condition: Depressive Disorder, Major
Interventions: Drug: Lu AA21004; Drug: Lu AA21004; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsor: Pfizer
Not yet recruiting - verified September 2010
Condition: Hypercholesterolemia
Intervention: Biological: REGN727
Sponsor: Regeneron Pharmaceuticals
Recruiting - verified August 2010
Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Intervention: Drug: XmAb®5574
Sponsor: Xencor, Inc.
Recruiting - verified September 2010
Condition: Non-squamous Non-small Cell Lung Cancer
Interventions: Drug: Paclitaxel / Carboplatin; Drug: bavituximab
Sponsor: Peregrine Pharmaceuticals
Recruiting - verified July 2010
Conditions: Clear Cell Renal Cell Carcinoma; Stage IV Renal Cell Cancer
Interventions: Drug: sunitinib malate; Other: laboratory biomarker analysis; Genetic: reverse transcriptase-polymerase chain reaction; Genetic: polymorphism analysis
Sponsor: Case Comprehensive Cancer Center
Recruiting - verified August 2010
Condition: Non-24-Hour Sleep-Wake Disorder
Interventions: Drug: tasimelteon; Drug: Placebo
Sponsor: Vanda Pharmaceuticals
Recruiting - verified September 2010
Condition: Refractory Multiple Myeloma
Interventions: Drug: azacitidine; Drug: lenalidomide; Drug: dexamethasone; Other: DNA methylation analysis; Other: gene expression analysis; Other: bone marrow aspiration; Other: immunohistochemistry staining method; Other: reverse transcriptase-polymerase chain reaction; Other: flow cytometry
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Minimal Residual Disease; Leukemia, Lymphoblastic, Acute; Leukemia, Myelogenous, Acute
Interventions: Drug: Clofarabine; Drug: Cytarabine; Drug: Methotrexate; Drug: Cytarabine
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Genzyme
Recruiting - verified August 2010
Condition: Kidney Transplantation
Interventions: Drug: Anti-Thymocyte Globulin; Drug: TOL101; Drug: TOL101; Drug: Steroids; Drug: Tacrolimus; Drug: Mycophenolate mofetil (MMF)
Sponsor: Tolera Therapeutics, Inc
Recruiting - verified August 2010
Condition: Colorectal Cancer
Interventions: Drug: celecoxib; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Asthma
Intervention: Device: Alair system
Sponsors: Washington University School of Medicine; The Cleveland Clinic; Mayo Clinic; National Jewish Health; University of Wisconsin, Madison; University of Chicago
Recruiting - verified August 2010
Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsor: Sanofi-Aventis
Recruiting - verified August 2010
Condition: Escherichia Coli Infections
Intervention: Biological: Double Mutant Heat- Labile Toxin (dmLT)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2010
Condition: Meningococcal Meningitis
Interventions: Biological: Meningococcal ACWY conjugate vaccine; Biological: Meningococcal ACWY conjugate vaccine
Sponsors: Novartis; Novartis Vaccines
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: LY2189265
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Conditions: Ureteral Calculi; Kidney Stones; Urolithiasis
Interventions: Drug: silodosin; Drug: placebo
Sponsor: Watson Pharmaceuticals
Recruiting - verified August 2010
Condition: Infertility
Interventions: Biological: SCH 900962 / Corifollitropin alfa / Org 36286; Biological: RecFSH / follitropin beta
Sponsor: Schering-Plough
Recruiting - verified August 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Exenatide Once Weekly; Drug: Placebo
Sponsors: Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified September 2010
Condition: Multiple Sclerosis
Interventions: Drug: ELND002; Drug: Placebo
Sponsor: Elan Pharmaceuticals
Recruiting - verified September 2010
Condition: Acne
Interventions: Drug: adapalene and benzoyl peroxide; Drug: Topical Gel Vehicle
Sponsor: Galderma
Recruiting - verified August 2010
Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Placebo
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified June 2010
Condition: Acute Gout
Interventions: Drug: ACZ885 (Canakinumab); Drug: Triamcinolone acetonide
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Sitagliptin 100 mg; Drug: Canagliflozin 300 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept; Drug: Methotrexate; Drug: Abatacept Placebo; Drug: Methotrexate Placebo
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified June 2010
Condition: Thrombosis
Intervention: Procedure: No Intervention
Sponsors: Bristol-Myers Squibb; Pfizer
Not yet recruiting - verified August 2010
Condition: Hyperglycemia
Interventions: Drug: Human regular insulin; Drug: Insulin lispro; Drug: Insulin glargine
Sponsor: Eli Lilly and Company
Not yet recruiting - verified August 2010
Condition: Hepatocellular Carcinoma
Interventions: Drug: Placebo; Biological: Ramucirumab DP
Sponsor: ImClone LLC
Recruiting - verified August 2010
Condition: Neoplasm Malignant
Intervention: Drug: Cabazitaxel (XRP6258)
Sponsor: Sanofi-Aventis
Recruiting - verified August 2010
Condition: Haemophilia A
Interventions: Drug: recombinant factor VIII (N8); Drug: recombinant factor VIII (N8)
Sponsor: Novo Nordisk
Recruiting - verified August 2010
Condition: Endometrial Cancer
Interventions: Drug: cediranib maleate; Other: laboratory biomarker analysis
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Rectal Cancer
Intervention: Procedure: J Pouch
Sponsor: The Cleveland Clinic
Recruiting - verified August 2010
Condition: Irritable Bowel Syndrome
Intervention: Drug: JNJ-27018966
Sponsor: Furiex Pharmaceuticals, Inc
Recruiting - verified August 2010
Condition: Erectile Dysfunction
Interventions: Drug: Tadalafil; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Parkinson's Disease
Interventions: Drug: IPX066; Drug: Carbidopa/Levodopa/Entacapone
Sponsor: IMPAX Laboratories, Inc.
Recruiting - verified August 2010
Condition: Schizophrenia
Interventions: Drug: LY2140023; Drug: Olanzapine; Drug: Aripiprazole; Drug: Risperidone; Drug: Quetiapine
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Alzheimer's Disease
Intervention: Drug: Solanezumab
Sponsor: Eli Lilly and Company
Not yet recruiting - verified August 2010
Condition: Ulcerative Colitis
Intervention: Drug: MMX mesalamine/ mesalazine
Sponsor: Shire Pharmaceutical Development
Recruiting - verified August 2010
Condition: Type 1 Diabetes Mellitus
Interventions: Biological: Otelixizumab; Biological: Placebo
Sponsors: Tolerx Inc.; Juvenile Diabetes Research Foundation; GlaxoSmithKline
Recruiting - verified May 2010
Condition: Asthma
Interventions: Drug: Tiotropium bromide; Drug: tiotropium bromide; Drug: tiotropium bromide; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified August 2010
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium 2.5 mcg; Drug: tiotropium 5 mcg; Drug: Tiotropium 18 mcg; Drug: placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Condition: Schizophrenia
Interventions: Drug: olanzapine; Drug: paliperidone; Drug: quetiapine; Drug: paliperidone palmitate; Drug: haloperidole; Drug: aripiprazole; Drug: risperidone; Drug: perphenazine
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified August 2010
Condition: Pelvic Pain Associated With Refractory Endometriosis
Interventions: Drug: BGS649; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified May 2010
Condition: Chronic Pain
Intervention: Drug: Hydrocodone bitartrate
Sponsor: Zogenix, Inc.
Recruiting - verified August 2010
Condition: Mycobacterium Tuberculosis
Interventions: Drug: Isoniazid; Biological: BCG
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified March 2010
Condition: Osteoarthritis of the Knee
Interventions: Drug: PENNSAID Gel; Drug: Vehicle
Sponsor: Mallinckrodt
Recruiting - verified August 2010
Conditions: Diabetic Kidney Disease; Diabetic Nephropathy; Diabetic Glomerulosclerosis
Interventions: Drug: LY2382770; Drug: Placebo
Sponsors: Eli Lilly and Company; Collaborative Study Group (CSG)
Recruiting - verified August 2010
Condition: Dyslipidemia
Interventions: Drug: BMS-823778; Drug: BMS-823778; Drug: BMS-823778; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified July 2010
Condition: Severe Congenital Protein C Deficiency
Intervention: Biological: Protein C Concentrate (Human)
Sponsors: Baxter Healthcare Corporation; American Thrombosis and Hemostasis Network; UDC Rare Bleeding and Clotting Disorders Working Group (RBDWG)
Recruiting - verified August 2010
Condition: Breast Cancer
Intervention: Drug: Gadobutrol (Gadovist, BAY86-4875)
Sponsor: Bayer
Recruiting - verified August 2010
Condition: Psoriasis
Interventions: Biological: LY2439821; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Conditions: Breast Cancer; Melanoma
Intervention: Drug: Lymphoseek
Sponsor: Neoprobe Corporation
Recruiting - verified August 2010
Condition: Acute Myeloid Leukemia (AML)
Interventions: Drug: Elacytarabine; Drug: Investigator's Choice
Sponsor: Clavis Pharma
Recruiting - verified September 2010
Condition: Sexual Dysfunctions, Psychological
Intervention: Drug: flibanserin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: DiaPep277; Drug: Placebo
Sponsor: Andromeda Biotech Ltd.
Recruiting - verified August 2010
Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: RO5185426; Drug: RO5185426; Drug: RO5185426; Drug: RO5185426
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Condition: Osteoarthritis
Interventions: Drug: PH-797804; Drug: Placebo; Drug: Placebo; Drug: PH-797804; Drug: Naproxen; Drug: Naproxen + PH-797804; Drug: Naproxen + PH-797804; Drug: Naproxen
Sponsor: Pfizer
Recruiting - verified August 2010
Conditions: Ileostomy; Colorectal Surgery
Intervention: Biological: AlloMEM™
Sponsor: University Hospitals of Cleveland
Recruiting - verified August 2010
Condition: Cervical Cancer
Interventions: Drug: cisplatin; Radiation: external beam radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Colon Cancer; Rectal Cancer
Interventions: Drug: mFOLFOX-6; Biological: IMC-1121B; Biological: IMC-18F1
Sponsor: ImClone LLC
Recruiting - verified August 2010
Conditions: Vasomotor Symptoms; Menopause
Intervention: Drug: Mesafem Capsules
Sponsor: Noven Pharmaceuticals
Recruiting - verified August 2010
Conditions: Acute Coronary Syndrome; Gout
Interventions: Drug: Febuxostat; Drug: Allopurinol
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: CS-7017; Drug: erlotinib
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified August 2010
Condition: Diarrhea Predominant Irritable Bowel Syndrome
Interventions: Drug: Asimadoline; Drug: Placebo
Sponsors: Tioga Pharmaceuticals; RTI Health Solutions
Recruiting - verified August 2010
Condition: Disease, Hodgkin
Interventions: Drug: brentuximab vedotin; Drug: placebo
Sponsors: Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified August 2010
Conditions: Complicated Skin and Skin Structure Infections; S. Aureus Bacteremia; Renal Impairment
Interventions: Drug: Vancomycin; Drug: Vancomycin; Drug: Daptomycin 7-14 days moderate renal impairment; Drug: Daptomycin 7 - 14 days severe renal impairment, hemodialysis; Drug: Daptomycin 7 - 14 days severe renal impairment no hemodialysis; Drug: Daptomycin 14 - 42 days, moderate renal impairment; Drug: Daptomycin 14 - 42 days, severe renal impairment on hemodialysis; Drug: Daptomycin 14 - 42 days severe renal impairment, no hemodialysis
Sponsor: Cubist Pharmaceuticals
Recruiting - verified August 2010
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: ACT-293987; Drug: Placebo
Sponsor: Actelion
Recruiting - verified August 2010
Condition: Major Depressive Disorder
Interventions: Drug: CP-601,927; Other: Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Canagliflozin 300 mg; Drug: sitaliptin 100 mg; Drug: Placebo/ sitagliptin 100 mg; Drug: Canagliflozin 100 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: adalimumab; Drug: placebo; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Canagliflozin 100 mg; Drug: Canagliflozin 300 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Canagliflozin 100 mg; Drug: Placebo/sitaliptin 100 mg; Drug: Canagliflozin 300 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Canagliflozin 100 mg; Drug: Canagliflozin 300 mg; Drug: Placebo
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Condition: Benign Prostatic Hyperplasia
Interventions: Drug: LY500307; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Colorectal Cancer
Intervention: Drug: Capecitabine + Perifosine or Placebo
Sponsor: Keryx / AOI Pharmaceuticals, Inc.
Recruiting - verified August 2010
Conditions: Diabetes Mellitus, Type 2; Hypertension
Interventions: Drug: Placebo; Drug: 1 mg PF-04971729; Drug: 5 mg PF-04971729; Drug: 25 mg PF-04971729; Drug: 12.5mg HCTZ
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Parkinson's Disease
Intervention: Drug: IPX066
Sponsor: IMPAX Laboratories, Inc.
Recruiting - verified August 2010
Conditions: Osteoarthritis; Osteoarthritis, Knee; Pain; Arthralgia; Joint Pain
Interventions: Drug: JNJ-42160443; Drug: placebo; Drug: JNJ-42160443; Drug: standard pain medication
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: sorafenib tosylate
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Breast Cancer
Interventions: Drug: brostallicin; Drug: cisplatin; Other: laboratory biomarker analysis
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: dexamethasone; Drug: gamma-secretase inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Acute Coronary Syndrome
Intervention: Drug: ADP receptor inhibitors
Sponsors: Eli Lilly and Company; Daiichi Sankyo Inc.
Recruiting - verified August 2010
Condition: Spondolyarthropathies
Interventions: Biological: Certolizumab pegol; Biological: Certolizumab pegol; Other: Placebo
Sponsor: UCB, Inc.
Recruiting - verified September 2010
Condition: Arthritis, Psoriatic
Interventions: Biological: CZP 200mg Q2W; Biological: CZP 400mg Q4W; Other: Placebo
Sponsor: UCB, Inc.
Recruiting - verified August 2010
Condition: Head and Neck Neoplasms
Interventions: Drug: Pemetrexed; Drug: Cetuximab; Drug: Carboplatin; Drug: Cisplatin
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Breast Cancer
Intervention: Drug: pixantrone dimaleate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Schizophrenia
Interventions: Drug: Risperidone; Drug: Placebo; Drug: LY2140023
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ABT-263; Drug: rituximab
Sponsors: Genentech; Abbott
Recruiting - verified August 2010
Conditions: Glioblastoma; Gliosarcoma; Brain Tumor
Interventions: Radiation: radiosurgery; Biological: bevacizumab; Drug: irinotecan hydrochloride
Sponsor: Case Comprehensive Cancer Center
Recruiting - verified September 2010
Conditions: Cardiomyopathy; Pregnancy
Intervention:
Sponsors: University of Pittsburgh; National Institutes of Health (NIH)
Recruiting - verified August 2010
Conditions: Head and Neck Cancer; Precancerous Condition
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: CDI; Clostridium Difficile Infection; Diarrhea
Intervention: Drug: CB-183,315
Sponsor: Cubist Pharmaceuticals
Recruiting - verified September 2010
Condition: Hematological Malignancy
Intervention: Drug: SAR650984
Sponsor: Sanofi-Aventis
Recruiting - verified August 2010
Condition: Lupus Arthritis
Interventions: Drug: Laquinimod; Drug: Laquinimod; Other: Placebo
Sponsor: Teva Pharmaceutical Industries
Recruiting - verified August 2010
Condition: Squamous Cell Lung Cancer
Interventions: Drug: gemcitabine/carboplatin; Drug: gemcitabine/carboplatin plus BSI-201
Sponsors: BiPar Sciences; Sanofi-Aventis
Recruiting - verified August 2010
Condition: Chronic Low Back Pain
Interventions: Drug: Placebo; Drug: Hydrocodone bitartrate
Sponsor: Zogenix, Inc.
Recruiting - verified August 2010
Condition: Lupus Nephritis
Interventions: Drug: laquinimod 0.5mg + standard of care; Drug: laquinimod 1mg + standard of care; Other: placebo + standard of care
Sponsor: Teva Pharmaceutical Industries
Recruiting - verified August 2010
Condition: Multiple Sclerosis
Interventions: Drug: ONO-4641; Drug: ONO-4641; Drug: ONO-4641; Drug: ONO-4641 placebo
Sponsor: Ono Pharma
Recruiting - verified September 2010
Condition: Attention-Deficit/Hyperactivity Disorder
Interventions: Drug: Extended-release Guanfacine Hydrochloride; Other: Placebo
Sponsor: Shire Pharmaceutical Development
Recruiting - verified August 2010
Conditions: Mild Cognitive Impairment; Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); National Institute on Aging (NIA); National Institutes of Health (NIH)
Recruiting - verified August 2010
Condition: Chronic Hepatitis C Virus Infection
Interventions: Drug: telaprevir; Drug: VX-222; Drug: ribavirin; Biological: peginterferon-alfa-2a; Drug: VX-222
Sponsor: Vertex Pharmaceuticals Incorporated
Recruiting - verified August 2010
Condition: Joint Damage
Interventions: Drug: Febuxostat; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
Conditions: Smoking Cessation; Depression
Interventions: Drug: varenicline; Drug: placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Hypertension
Interventions: Drug: Azilsartan medoxomil (TAK-491); Drug: Azilsartan medoxomil (TAK-491); Drug: Azilsartan medoxomil (TAK-491); Drug: Azilsartan medoxomil (TAK-491)
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
Condition: Morbid Obesity
Intervention: Procedure: Gastric Plication
Sponsor: Ethicon Endo-Surgery
Recruiting - verified August 2010
Condition: Familial Hypercholesterolaemia
Interventions: Drug: rosuvastatin calcium; Drug: rosuvastatin calcium; Drug: rosuvastatin calcium
Sponsor: AstraZeneca
Recruiting - verified August 2010
Condition: Acute Coronary Syndrome
Interventions: Drug: eptifibatide; Drug: unfractionated heparin placebo; Drug: unfractionated heparin; Drug: otamixaban (XRP0673); Drug: eptifibatide placebo; Drug: otamixaban placebo
Sponsor: Sanofi-Aventis
Recruiting - verified August 2010
Condition: Arthritis, Psoriatic
Interventions: Drug: ustekinumab; Drug: placebo; Drug: ustekinumab; Drug: placebo; Drug: ustekinumab; Drug: placebo; Drug: ustekinumab; Drug: ustekinumab
Sponsor: Centocor, Inc.
Recruiting - verified August 2010
Conditions: Arrhythmia; Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified August 2010
Conditions: Arrhythmia; Bradycardia
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified August 2010
Conditions: Arrhythmia; Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified August 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: bortezomib; Drug: carboplatin; Other: pharmacological study
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Trauma
Intervention:
Sponsors: University of Cincinnati; Henry M Jackson Foundation
Recruiting - verified August 2010
Condition: Community Acquired Pneumonia
Interventions: Drug: Zabofloxacin; Drug: Levofloxacin 500mg; Drug: Zabofloxacin 400mg
Sponsor: Pacific Beach BioSciences, Inc.
Recruiting - verified August 2010
Conditions: Alzheimer's Disease; Central Nervous System Diseases; Cognition
Interventions: Drug: EVP-6124; Drug: Placebo
Sponsors: EnVivo Pharmaceuticals, Inc.; INC Research Limited
Recruiting - verified August 2010
Condition: Pancreatic Cancer
Intervention: Biological: HyperAcute-Pancreatic Cancer Vaccine
Sponsor: NewLink Genetics Corporation
Recruiting - verified August 2010
Condition: Idiopathic Pulmonary Fibrosis
Intervention:
Sponsors: University of Michigan; National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH)
Recruiting - verified November 2009
Condition: Urinary Incontinence
Intervention: Device: Athena Pelvic Muscle Trainer
Sponsor: Athena Feminine Technologies, Inc.
Recruiting - verified September 2010
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: natalizumab; Drug: interferon beta 1-a; Drug: methylprednisolone; Other: IV placebo; Drug: glatiramer acetate
Sponsors: Biogen Idec; Elan Pharmaceuticals
Recruiting - verified August 2010
Condition: Intra-abdominal Infection
Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039); Drug: Ertapenem, Amoxicillin/clavulanate
Sponsor: Bayer
Recruiting - verified August 2010
Condition: Influenza
Interventions: Drug: Favipiravir; Drug: Favipiravir; Drug: Placebo comparator
Sponsor: Toyama Chemical Co., Ltd.
Recruiting - verified August 2010
Condition: Astrocytic Tumors
Intervention: Drug: XL184
Sponsor: Exelixis
Recruiting - verified August 2010
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Glatiramer acetate (GA); Other: Placebo
Sponsor: Teva Pharmaceutical Industries
Recruiting - verified August 2010
Conditions: Hypertension, Pulmonary; Ventricular Dysfunction, Left
Interventions: Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Exenatide; Drug: LY2189265; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Respiratory Syncytial Virus Infections
Interventions: Drug: ALN-RSV01; Drug: Normal Saline
Sponsor: Alnylam Pharmaceuticals
Recruiting - verified August 2010
Conditions: Diabetes Mellitus, Type 2; Renal Insufficiency
Interventions: Drug: Canagliflozin 300 mg; Drug: Placebo; Drug: Canagliflozin 100 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Conditions: Chronic Optic Nerve Atrophy; Non-Arteritic Anterior Ischemic Optic Neuropathy
Intervention: Drug: QPI-1007 at various doses
Sponsor: Quark Pharmaceuticals
Recruiting - verified August 2010
Condition: Tachycardia, Ventricular
Intervention: Device: S-ICD System
Sponsor: Cameron Health, Inc.
Recruiting - verified August 2010
Condition: Influenza
Intervention: Drug: Peramivir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified January 2010
Conditions: Erectile Dysfunction; Sexual Dysfunction
Interventions: Drug: Placebo; Drug: Dapoxetine
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cediranib maleate; Drug: temozolomide; Other: placebo; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Myelodysplastic Syndrome
Interventions: Drug: Ezatiostat Hydrochloride; Drug: Lenalidomide (Revlimid®)
Sponsor: Telik
Recruiting - verified February 2010
Condition: Ankylosing Spondylitis
Interventions: Drug: SAR153191 (REGN88); Drug: placebo
Sponsors: Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified August 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: SAR153191(REGN88); Drug: placebo
Sponsors: Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified August 2010
Condition: Myopia
Interventions: Device: WAVEFRONT Optimized LASIK; Device: WAVEFRONT GUIDED LASIK
Sponsor: Innovative Medical
Recruiting - verified September 2010
Condition: Cardiovascular Disease
Interventions: Drug: dalcetrapib; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: CP-690,550; Drug: Atorvastatin; Drug: CP-690,550; Drug: Atorvastatin Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Hereditary Angioedema
Intervention:
Sponsor: Dyax Corp.
Recruiting - verified August 2010
Condition: Diabetic Neuropathy, Painful
Interventions: Drug: Pregabalin; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: Flibanserin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Condition: Infantile Hemangioma
Interventions: Drug: Propranolol; Drug: Placebo
Sponsor: Pierre Fabre Dermatology
Recruiting - verified August 2010
Condition: Sarcoma
Interventions: Biological: cixutumumab; Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Lung Cancer
Interventions: Radiation: prophylactic cranial irradiation; Radiation: selective external radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Influenza
Intervention: Drug: oseltamivir [Tamiflu]
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified August 2010
Condition: Traumatic Brain Injury
Interventions: Behavioral: Internet-based Interacting Together Everyday: Recovery After Childhood TBI; Behavioral: Internet Resources Comparison
Sponsors: Children's Hospital Medical Center, Cincinnati; U.S. Department of Education
Recruiting - verified September 2010
Condition: Influenza
Interventions: Drug: Oseltamivir; Drug: Oseltamivir
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Conditions: Schizophrenia; Bipolar Disorder; Autistic Disorder; Attention Deficit and Disruptive Behavior Disorders
Interventions: Drug: Risperidone; Drug: Other atypical antipsychotic drugs
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Condition: Infections
Intervention: Drug: Moxifloxacin (Avelox, BAY12-8039)
Sponsor: Bayer
Recruiting - verified August 2010
Condition: Neuropathy
Interventions: Drug: pregabalin; Drug: placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Conditions: Adult Non-Hodgkin Lymphoma; Adult Grade III Lymphomatoid Granulomatosis; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Small Lymphocytic Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: lenalidomide; Biological: rituximab; Genetic: polymerase chain reaction; Genetic: nucleic acid sequencing; Genetic: polymorphism analysis; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsor: Case Comprehensive Cancer Center
Recruiting - verified August 2010
Condition: Gastroesophageal Reflux
Interventions: Drug: Dexlansoprazole; Drug: Dexlansoprazole; Drug: Dexlansoprazole
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Aleglitazar; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease; Inadequate Glycaemic Control
Interventions: Drug: Dapagliflozin; Drug: Placebo
Sponsors: AstraZeneca; Bristol-Myers Squibb
Recruiting - verified August 2010
Condition: Myeloma
Interventions: Drug: Bendamustine; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Aspirin; Drug: Prophylaxis; Drug: Antibiotic; Other: Biweekly Follow Up; Other: Cyclical Follow Up; Other: Restaging; Other: Post-Treatment Follow Up
Sponsors: University of Pittsburgh; Cephalon
Recruiting - verified August 2010
Condition: Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: carboplatin; Drug: cisplatin; Drug: etoposide phosphate; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Diabetic Neuropathy, Painful; Diabetic Polyneuropathy
Interventions: Drug: tapentadol extended release (ER); Drug: placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Grünenthal GmbH
Recruiting - verified August 2010
Conditions: Leukemia Lymphoblastic, Acute; Acute Myeloid Leukemia; Neoplasm Recurrent
Interventions: Drug: Clofarabine; Radiation: Total Body Irradiation; Other: Stem Cell Infusion; Drug: Cyclosporins; Drug: Mycophenolate mofetil
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Genzyme
Recruiting - verified August 2010
Conditions: Sexual Dysfunctions, Psychological; Depression
Interventions: Drug: flibanserin 2; Drug: placebo; Drug: flibanserin 1
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Condition: Breast Cancer
Interventions: Drug: YM155; Drug: Docetaxel
Sponsor: Astellas Pharma Inc
Recruiting - verified September 2010
Condition: Angioedema
Intervention: Drug: ecallantide - Kallikrein inhibitor that blocks the production of bradykinin
Sponsors: Bernstein, Jonathan A., M.D.; Dyax Corp.
Recruiting - verified December 2009
Condition: Ankle Sprain
Interventions: Drug: FS-67; Other: Placebo
Sponsor: Hisamitsu Pharmaceutical Co., Inc.
Recruiting - verified August 2010
Condition: Refractory Multiple Myeloma
Interventions: Drug: Aurora A kinase inhibitor MLN8237; Drug: bortezomib
Sponsor: Mayo Clinic
Recruiting - verified August 2010
Condition: Influenza
Intervention: Drug: oseltamivir [Tamiflu]
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified August 2010
Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases; Risk Factors
Interventions: Drug: Canagliflozin on background standard of care for diabetes; Drug: Placebo on background standard of care for diabetes
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; George Institute, Sydney, Australia
Recruiting - verified August 2010
Condition: Influenza
Interventions: Drug: Oseltamivir; Drug: Oseltamivir; Drug: Oseltamivir; Drug: Oseltamivir
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease; Hypertension; Inadequate Glycaemic Control
Interventions: Drug: Dapagliflozin; Drug: Placebo
Sponsors: AstraZeneca; Bristol-Myers Squibb
Recruiting - verified August 2010
Condition: Human Papillomavirus
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2010
Condition: Melanoma
Interventions: Drug: nilotinib (AMN107); Drug: decarbazine (DTIC)
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010
Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: prednisone; Drug: vincristine sulfate; Drug: vinorelbine ditartrate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Dilated Cardiomyopathy
Intervention: Biological: Cardiac Repair Cells (CRCs)
Sponsor: Aastrom Biosciences
Recruiting - verified August 2010
Condition: Perennial Allergic Rhinitis
Interventions: Drug: Azelastine hydrochloride nasal spray 0.15%; Drug: Azelastine hydrochloride nasal spray 0.10%; Drug: Placebo
Sponsor: Meda Pharmaceuticals
Recruiting - verified August 2010
Condition: Neoplasms
Intervention: Drug: BI 6727, IV infusion
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Condition: Fibromyalgia
Interventions: Drug: placebo; Drug: pregabalin
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Fibromyalgia
Intervention: Drug: pregabalin
Sponsor: Pfizer
Not yet recruiting - verified August 2010
Condition: Osteoarthritis Knee Pain
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Conditions: Pancreatic Cancer; Ductal Adrenocarcinoma; Exocrine Pancreatic Cancer
Intervention: Drug: PCI-27483
Sponsor: Pharmacyclics
Recruiting - verified June 2010
Condition: Cervical Intraepithelial Neoplasia
Interventions: Drug: RO5217790; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Condition: Lung Cancer
Interventions: Biological: Seneca Valley virus-001; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Liver Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: sorafenib tosylate
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: anti-CCR2 monoclonal antibody MLN1202; Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Sarcoma
Interventions: Biological: bevacizumab; Biological: filgrastim; Biological: pegfilgrastim; Drug: docetaxel; Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Colorectal Cancer; Precancerous Condition
Interventions: Drug: rosuvastatin; Other: placebo
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773; Drug: BI 10773
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Conditions: Ovarian Neoplasms; Peritoneal Neoplasms
Interventions: Drug: Placebo; Drug: BIBF 1120
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Conditions: Endometrial Cancer; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Liver Cancer; Lung Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Arthritis, Psoriatic
Interventions: Drug: ustekinumab; Drug: placebo; Drug: ustekinumab; Drug: placebo; Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: ustekinumab
Sponsor: Centocor, Inc.
Recruiting - verified August 2010
Conditions: Proctitis; Proctosigmoiditis
Interventions: Drug: Budesonide; Drug: Placebo
Sponsor: Salix Pharmaceuticals
Recruiting - verified August 2010
Conditions: Proctitis; Proctosigmoiditis
Interventions: Drug: Budesonide; Drug: Placebo
Sponsor: Salix Pharmaceuticals
Recruiting - verified August 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: methotrexate
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Condition: Melanoma
Interventions: Drug: Tasisulam; Drug: Paclitaxel
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel; Procedure: adjuvant therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: Southern blotting; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: mitomycin C; Drug: sorafenib tosylate; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Leukemia
Interventions: Genetic: fluorescence in situ hybridization; Genetic: mutation analysis; Genetic: nucleic acid sequencing; Genetic: polymerase chain reaction; Genetic: western blotting; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Leukemia
Intervention: Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases
Interventions: Drug: golimumab; Drug: golimumab or placebo; Drug: golimumab or placebo
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified August 2010
Condition: Preterm Birth
Interventions: Drug: Hydroxyprogesterone Caproate Injection, 250mg/mL; Drug: Vehicle
Sponsors: Hologic, Inc.; PRA International
Recruiting - verified August 2010
Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Gout
Interventions: Drug: RDEA594; Drug: Placebo; Drug: Allopurinol
Sponsor: Ardea Biosciences, Inc.
Recruiting - verified August 2010
Conditions: Low Bispectral Index; Low Mean Arterial Blood Pressure; Low End-tidal Anesthetic Concentration
Intervention:
Sponsor: Outcomes Research Consortium
Recruiting - verified August 2010
Condition: Coronary Artery Disease
Interventions: Device: TAXUS Liberté Paclitaxel-Eluting Coronary Stent; Drug: prasugrel; Drug: placebo; Drug: aspirin
Sponsors: Boston Scientific Corporation; Eli Lilly and Company; Daiichi Sankyo Inc.
Recruiting - verified September 2010
Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Recruiting - verified September 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin; Drug: Linagliptin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Conditions: Cancer Survivor; Fatigue; Psychosocial Effects of Cancer and Its Treatment; Sleep Disorders
Interventions: Behavioral: compliance monitoring; Other: educational intervention; Other: questionnaire administration; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment; Procedure: sleep disorder therapy; Procedure: stress management therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Essential Hypertension
Interventions: Drug: Azilsartan medoxomil and chlorthalidone; Drug: Olmesartan medoxomil and hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: belinostat; Drug: carboplatin
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Cirrhosis; Hepatic Encephalopathy
Interventions: Drug: HPN-100 (formerly known as GT4P); Drug: HPN-100 Placebo
Sponsor: Hyperion Therapeutics, Inc.
Recruiting - verified August 2010
Conditions: Pain; Diabetic Neuropathy, Painful
Interventions: Drug: Placebo; Drug: JNJ-42160443
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Conditions: Stage IV Breast Cancer; Central Nervous System Involvement/Metastases; Leptomeningeal Metastases; Recurrent Breast Cancer; Tumors Metastatic to Brain
Interventions: Drug: methotrexate; Drug: liposomal cytarabine; Other: quality-of-life assessment; Other: questionnaire administration
Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting - verified August 2010
Condition: Restless Legs Syndrome
Interventions: Drug: pregabalin; Drug: placebo; Drug: pramipexole
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Coronary Artery Disease
Interventions: Drug: Apadenoson; Drug: Adenosine
Sponsors: PGxHealth, LLC; PPD
Recruiting - verified August 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: paclitaxel; Drug: veliparib
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Hemiplegia
Intervention: Device: EMS 2000
Sponsor: Department of Veterans Affairs
Recruiting - verified August 2010
Condition: Partial Epilepsy
Interventions: Drug: Eslicarbazepine acetate; Drug: Eslicarbazepine acetate; Drug: Eslicarbazepine acetate
Sponsors: Bial - Portela C S.A.; Sepracor, Inc.
Recruiting - verified August 2010
Condition: Castrate-Resistant Prostate Cancer
Intervention: Drug: Lenalidomide (CC-5013) 10mg, 15mg, 20mg, 25mg and their respective matching placebo capsules for oral administration
Sponsor: Celgene Corporation
Recruiting - verified September 2010
Conditions: Tuberculosis; HIV
Interventions: Drug: Efavirenz (EFV); Drug: TMC207
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2009
Condition: Juvenile Idiopathic Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: placebo; Drug: NSAIDs, corticosteroids, methotrexate
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Condition: Lung Cancer
Interventions: Biological: cetuximab; Biological: cixutumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Pain; Back Pain; Low Back Pain; Back Pain With Radiation
Interventions: Drug: Oxycodone IR; Drug: NUCYNTA
Sponsors: Ortho-McNeil Janssen Scientific Affairs, LLC; Grünenthal
Recruiting - verified August 2010
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: YM155; Biological: Rituximab
Sponsor: Astellas Pharma Inc
Recruiting - verified August 2010
Conditions: Adenocarcinoma of the Gastroesophageal Junction; Gastric Cancer
Interventions: Drug: FOLFOX regimen; Drug: Hedgehog antagonist GDC-0449; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: New York Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Hepatitis C; HIV Infections
Interventions: Drug: telaprevir or matching placebo; Drug: telaprevir or matching placebo; Biological: peginterferon alfa-2a; Drug: ribavirin (fixed dose); Drug: ribavirin (weight-based dose)
Sponsors: Vertex Pharmaceuticals Incorporated; Tibotec Pharmaceutical Limited
Recruiting - verified August 2010
Condition: Haemophilia A
Interventions: Drug: recombinant factor VIII (N8); Drug: recombinant factor VIII (N8)
Sponsor: Novo Nordisk
Recruiting - verified September 2010
Condition: Bladder Cancer
Interventions: Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Cervical Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Biological: IMC-11F8
Sponsors: ImClone LLC; Parexel; PPD; Medidata; Laboratory Corporation of America; University of Colorado, Denver; Fisher Clinical Services; ICON Medical Imaging
Recruiting - verified August 2010
Condition: Breast Cancer
Interventions: Drug: BIIB021; Drug: BIIB021; Drug: exemestane (Aromasin)
Sponsor: Biogen Idec
Recruiting - verified August 2010
Condition: Ovarian Cancer
Interventions: Drug: sunitinib malate; Other: laboratory biomarker analysis
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Brain and Central Nervous System Tumors; Neurotoxicity
Interventions: Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Chemotherapeutic Agent Toxicity; Fallopian Tube Cancer; Neurotoxicity; Ovarian Cancer; Pain; Peripheral Neuropathy; Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: glutathione; Drug: paclitaxel; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Bipolar I Disorder; Schizophrenia
Interventions: Drug: Olanzapine; Behavioral: Standard behavioral weight intervention; Behavioral: Intense behavioral weight intervention
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Multiple System Atrophy
Interventions: Drug: rasagiline mesylate; Other: placebo
Sponsors: Teva Pharmaceutical Industries; H. Lundbeck A/S
Recruiting - verified August 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Lixisenatide (AVE0010); Drug: Sitagliptin
Sponsor: Sanofi-Aventis
Recruiting - verified September 2010
Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ixabepilone; Drug: paclitaxel; Drug: temsirolimus
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: erlotinib hydrochloride; Drug: paclitaxel; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: CP-690,550 + methotrexate; Drug: Placebo + Methotrexate
Sponsor: Pfizer
Recruiting - verified August 2010
Conditions: Kaposiform Hemangioendotheliomas; Tufted Angioma; Capillary Venous Lymphatic Malformation; Venous Lymphatic Malformation; Microcystic Lymphatic Malformation; Mucocutaneous Lymphangiomatosis and Thrombocytopenia; Capillary Lymphatic Arterial Venous Malformations; PTEN Overgrowth Syndrome With Vascular Anomaly; Lymphangiectasia Syndromes
Intervention: Drug: sirolimus
Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting - verified August 2010
Condition: Hyperparathyroidism, Primary
Interventions: Drug: cinacalcet HCl; Drug: Placebo
Sponsor: Amgen
Recruiting - verified August 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo; Drug: insulin glargine (HOE901)
Sponsor: Sanofi-Aventis
Recruiting - verified August 2010
Conditions: Relapsed T-Cell Acute Lymphoblastic Leukemia; Relapsed T-Cell Lymphoblastic Lymphoma
Interventions: Drug: Nelarabine; Drug: Etoposide; Drug: Cyclophosphamide; Drug: Methotrexate; Drug: Filgrastim
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; GlaxoSmithKline
Recruiting - verified August 2010
Condition: Renal Cell Carcinoma
Intervention: Drug: Lenalidomide (CC-5013) in combination with sunitinib
Sponsor: Celgene Corporation
Recruiting - verified August 2010
Condition: Arthritis, Rheumatoid
Interventions: Biological: golimumab; Biological: golimumab; Biological: golimumab; Drug: placebo
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified August 2010
Condition: Gastroesophageal Reflux
Interventions: Drug: Rabeprazole sodium capsules; Drug: Rabeprazole sodium capsules; Drug: placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Eisai Inc.
Recruiting - verified August 2010
Condition: Acute On Chronic Hepatitis
Interventions: Device: Extracorporeal Liver Assist Device (ELAD); Other: Standard of care
Sponsor: Vital Therapies, Inc.
Recruiting - verified May 2010
Condition: Acute Cardiac Dysfunction
Intervention: Device: AB Portable Driver System
Sponsor: Abiomed Inc.
Recruiting - verified August 2010
Condition: Cocaine Dependence
Interventions: Drug: TA-CD Vaccination; Other: Placebo Injection
Sponsors: National Institute on Drug Abuse (NIDA); US Department of Veterans Affairs Cooperative Studies Program; VA Maryland Health Care System; Baylor College of Medicine; Columbia University; VA New York Harbor Healthcare System; University of Pennsylvania; Johns Hopkins University; University of Cincinnati; Celtic Pharma Development Services
Recruiting - verified August 2010
Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: JNJ-28431754; Drug: glimepiride
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Conditions: Colorectal Cancer; Neoplasms, Colorectal
Interventions: Drug: CS7017; Drug: irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified August 2010
Condition: Epilepsy
Intervention: Drug: Melatonin
Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting - verified August 2010
Condition: Relapsed or Refractory Chronic Lymphocytic Leukemia
Intervention: Drug: lenalidomide
Sponsor: Celgene Corporation
Recruiting - verified August 2010
Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Spinal Cord Stimulation; Deep Brain Stimulation; Drug Infusion (Implantable Pumps); Sacral Nerve Stimulation
Intervention: Device: Various
Sponsor: MedtronicNeuro
Recruiting - verified August 2010
Conditions: Cough; Sore Throat; Nasal Congestion; Headache; Fever; Seasonal Influenza
Interventions: Drug: Peramivir 600mg Adults, Peramivir 10mg/kg Adolescents; Drug: Placebo Peramivir
Sponsors: BioCryst Pharmaceuticals; Department of Health and Human Services
Recruiting - verified July 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer; Psychosocial Effects of Cancer and Its Treatment
Interventions: Other: communication intervention; Other: educational intervention; Other: internet-based intervention; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: management of therapy complications; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Treatment Resistant Depression
Interventions: Drug: Olanzapine and Fluoxetine combination; Drug: Fluoxetine
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Conditions: Breast Cancer; Hot Flashes; Menopausal Symptoms; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Dietary Supplement: flaxseed; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cixutumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Ovarian Cancer; Sarcoma
Interventions: Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Sarcoidosis
Interventions: Drug: Placebo; Drug: golimumab; Drug: ustekinumab
Sponsor: Centocor, Inc.
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Linagliptin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Related Hematopoietic Stem Cell Donors
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; National Institutes of Health (NIH); University of Utah; University of Pittsburgh
Recruiting - verified August 2010
Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel; Biological: Bevacizumab
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Factor XIII Deficiency
Intervention: Biological: FXIII Concentrate Human
Sponsor: CSL Behring
Recruiting - verified August 2010
Conditions: Hemophilia A; Hemophilia B
Intervention: Drug: Ataluren (PTC124)
Sponsors: PTC Therapeutics; Genzyme
Recruiting - verified August 2010
Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: vincristine sulfate; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Glioblastoma
Interventions: Drug: bevacizumab [Avastin]; Drug: Placebo; Drug: temozolomide; Radiation: Radiation therapy
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Conditions: Brain and Central Nervous System Tumors; Lymphoma; Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: crizotinib; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Melanoma (Skin)
Intervention: Drug: dinaciclib
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Magnetic Resonance Imaging
Intervention: Drug: Gadopentetate dimeglumine (Magnevist, BAY86-6661)
Sponsor: Bayer
Recruiting - verified August 2010
Condition: Postmenopausal Osteoporosis
Interventions: Drug: Ibandronate; Drug: Denosumab
Sponsor: Amgen
Recruiting - verified August 2010
Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Carcinoma of Unknown Primary
Interventions: Drug: carboplatin; Drug: everolimus; Drug: paclitaxel; Genetic: gene expression analysis; Other: laboratory biomarker analysis
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept; Drug: Adalimumab
Sponsor: Bristol-Myers Squibb
Recruiting - verified June 2010
Condition: Scleroderma
Interventions: Drug: MEDI-546; Drug: MEDI-546; Drug: MEDI-546; Drug: MEDI-546; Drug: MEDI-546; Drug: MEDI-546; Drug: MEDI-546; Drug: MEDI-546
Sponsor: MedImmune LLC
Recruiting - verified September 2010
Conditions: Brain and Central Nervous System Tumors; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: pazopanib hydrochloride; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Total Knee Replacement Surgery
Interventions: Procedure: stimulation needle and stimulating catheter; Procedure: nerve catheter with stimulating needle; Procedure: guided femoral nerve block without stimulation
Sponsor: Outcomes Research Consortium
Recruiting - verified August 2010
Condition: Fabry Disease
Interventions: Drug: migalastat hydrochloride; Drug: Placebo
Sponsor: Amicus Therapeutics
Recruiting - verified August 2010
Condition: Phenylketonuria
Intervention: Drug: rAvPAL-PEG
Sponsor: BioMarin Pharmaceutical
Recruiting - verified September 2010
Conditions: Cryptogenic Symptomatic Transient Ischemic Attack; Cryptogenic Ischemic Stroke
Intervention: Device: Reveal® XT Insertable Cardiac Monitor
Sponsors: Medtronic Cardiac Rhythm Disease Management; Medtronic Bakken Research Center
Recruiting - verified August 2010
Conditions: Metastatic Cancer; Pain
Interventions: Radiation: external beam radiation therapy; Radiation: image-guided radiation therapy; Radiation: radiosurgery; Radiation: stereotactic body radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: LY2216684; Drug: Methylphenidate; Drug: Placebo (tablet); Drug: Placebo (capsule)
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Benign Prostatic Hyperplasia
Interventions: Drug: NX-1207; Drug: Placebo
Sponsor: Nymox Corporation
Recruiting - verified August 2010
Condition: Glioblastoma Multiforme
Interventions: Device: NovoTTF-100A device; Drug: Temozolomide
Sponsor: NovoCure Ltd.
Recruiting - verified August 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: Everolimus; Drug: Bevacizumab; Drug: Paclitaxel; Drug: Placebo; Drug: Bevacizumab; Drug: Paclitaxel
Sponsors: Sarah Cannon Research Institute; Novartis
Recruiting - verified August 2010
Condition: Hereditary Angioedema
Interventions: Drug: Icatibant; Drug: Placebo
Sponsors: Jerini AG; Shire Human Genetic Therapies, Inc.
Recruiting - verified August 2010
Condition: Autism
Intervention: Drug: CM-AT
Sponsor: Curemark
Recruiting - verified August 2010
Condition: Overactive Bladder
Interventions: Drug: Fesoterodine; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Non-CNS Solid Tumors
Intervention: Biological: HSV1716
Sponsors: Children's Hospital Medical Center, Cincinnati; FDA Office of Orphan Products Development
Recruiting - verified August 2010
Condition: Head and Neck Squamous Cell Carcinoma
Intervention: Procedure: Lymphoseek
Sponsor: Neoprobe Corporation
Recruiting - verified August 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Arformoterol; Drug: Placebo
Sponsor: Sepracor, Inc.
Recruiting - verified May 2010
Condition: Thrombosis
Intervention: Drug: Desirudin
Sponsor: Canyon Pharmaceuticals, Inc.
Recruiting - verified August 2010
Condition: Parkinson Disease
Interventions: Drug: isradipine cr; Drug: placebo/ sugar pill
Sponsors: The Parkinson Study Group; Michael J. Fox Foundation for Parkinson's Research; Northwestern University Dixon Fund
Recruiting - verified August 2010
Conditions: Cancer; Colon Cancer; Colorectal Cancer; Fever; Locally Advanced; Metastatic Colorectal Cancer; Neutropenia; Rectal Cancer
Interventions: Drug: Pegfilgrastim; Drug: Placebo
Sponsor: Amgen
Recruiting - verified September 2010
Condition: Relapsing Multiple Sclerosis
Intervention: Drug: BIIB017
Sponsor: Biogen Idec
Recruiting - verified August 2010
Condition: Alzheimer's Disease
Interventions: Drug: LY2062430; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Neuroblastoma
Interventions: Genetic: loss of heterozygosity analysis; Other: cytology specimen collection procedure; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: QTI571; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Commercial Ventavis® (iloprost)
Sponsor: Actelion
Recruiting - verified August 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
Sponsor: Bayer
Recruiting - verified August 2010
Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Lymphoma
Interventions: Other: biologic sample preservation procedure; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Lymphoma
Intervention: Other: cryopreservation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Intervention: Other: laboratory biomarker analysis
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition
Interventions: Genetic: cytogenetic analysis; Genetic: microarray analysis; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: DNA methylation analysis; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: high performance liquid chromatography; Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Prostate Cancer
Interventions: Genetic: microarray analysis; Other: laboratory biomarker analysis
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Other: biologic sample preservation procedure
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: methoxyamine; Drug: temozolomide; Genetic: DNA analysis; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Drug: capecitabine; Drug: sunitinib malate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: Nonbiologic DMARDs of investigator's choice
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Condition: Alzheimer's Disease
Interventions: Drug: BMS-708163; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified June 2010
Conditions: Graft Rejection; Kidney Transplant; Renal Allograft Recipients; Renal Transplant
Interventions: Drug: Tacrolimus; Drug: Sirolimus; Drug: Tacrolimus
Sponsor: Wyeth
Recruiting - verified August 2010
Condition: Crohn's Disease
Interventions: Drug: certolizumab pegol; Drug: certolizumab pegol
Sponsor: UCB, Inc.
Recruiting - verified September 2010
Condition: Ulcerative Colitis
Intervention: Biological: Lactobacillus GG
Sponsor: Children's Hospital Medical Center, Cincinnati
Not yet recruiting - verified August 2010
Condition: Non-Cystic Fibrosis Bronchiectasis
Interventions: Drug: Ciprofloxacin for Inhalation; Drug: Ciprofloxacin for Inhalation; Drug: Placebo
Sponsor: Aradigm Corporation
Recruiting - verified August 2010
Condition: Renal Cell Carcinoma
Interventions: Drug: RAD001; Drug: sunitinib
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: docetaxel; Drug: doxorubicin; Drug: cyclophosphamide; Drug: cyclophosphamide; Drug: pegfilgrastim
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); Genentech; US Oncology Research
Recruiting - verified August 2010
Condition: Myeloid Leukemia
Intervention: Biological: IMC-EB10
Sponsor: ImClone LLC
Recruiting - verified August 2010
Condition: Lung Cancer
Interventions: Biological: cixutumumab; Drug: Hedgehog antagonist GDC-0449; Drug: cisplatin; Drug: etoposide phosphate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Radiation: radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer
Recruiting - verified August 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: temozolomide; Other: placebo
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: LY2127399; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Breast Cancer
Interventions: Drug: systemic chemotherapy; Procedure: axillary lymph node dissection; Procedure: neoadjuvant therapy; Procedure: sentinel lymph node biopsy; Procedure: therapeutic conventional surgery; Procedure: ultrasound imaging
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Autism
Interventions: Drug: CM-AT; Drug: Placebo
Sponsor: Curemark
Recruiting - verified August 2010
Conditions: Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: dexamethasone; Drug: gabapentin; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Articular Cartilage Injury; Osteochondritis Dissecans
Interventions: Procedure: Microfracture; Procedure: Cartilage Autograft Implantation System
Sponsor: Advanced Technologies and Regenerative Medicine, LLC (ATRM)
Recruiting - verified August 2010
Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: cixutumumab; Drug: temsirolimus; Genetic: gene expression analysis; Genetic: protein expression analysis; Genetic: western blotting; Other: immunologic technique; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Myocardial Infarction
Interventions: Drug: Prochymal®; Drug: Placebo
Sponsor: Osiris Therapeutics
Recruiting - verified August 2010
Conditions: Leukemia; Lymphoma
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: bortezomib; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: docetaxel; Drug: vandetanib
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Autism
Interventions: Drug: Memantine-HCl; Drug: Placebo
Sponsors: Forest Laboratories; Merz Pharmaceuticals GmbH
Recruiting - verified August 2010
Conditions: Solid Tumors; Lymphoma, Non-Hodgkin; Multiple Myeloma; Leukemia, Lymphocytic, Chronic. B-Cell
Intervention: Drug: SCH 727965
Sponsor: Schering-Plough
Recruiting - verified August 2010
Condition: Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified August 2010
Condition: Diabetic Neuropathies
Interventions: Drug: Placebo; Drug: Carisbamate 1,200 mg/d; Drug: Pregabalin 300 mg/d; Drug: Carisbamate 800 mg/d
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Conditions: Breast Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Musculoskeletal Complications; Pain; Prostate Cancer; Urinary Complications
Intervention: Drug: zoledronic acid
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Anterior Ischemic Optic Neuropathy
Intervention: Drug: Diagnostic procedures
Sponsor: Bayer
Recruiting - verified September 2010
Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: idarubicin; Drug: mercaptopurine; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: tretinoin; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ABT-263; Drug: FCR; Drug: BR
Sponsors: Abbott; Genentech
Recruiting - verified June 2010
Condition: Malignant Melanoma
Interventions: Drug: ABI-007; Drug: Dacarbazine
Sponsors: Abraxis BioScience Inc.; University of Arizona
Recruiting - verified April 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified July 2010
Conditions: Chemotherapeutic Agent Toxicity; Neurotoxicity; Pain; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: paclitaxel; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: assessment of therapy complications
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Hepato Cellular Carcinoma (HCC)
Interventions: Drug: Brivanib; Drug: Placebo; Drug: Sorafenib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified May 2010
Conditions: Insomnia; Attention Deficit Hyperactivity Disorder
Intervention: Drug: eszopiclone
Sponsor: Sepracor, Inc.
Recruiting - verified May 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Biological: pegfilgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Colorectal Cancer
Interventions: Other: medical chart review; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Other: survey administration
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Insomnia; Attention Deficit Hyperactivity Disorder
Interventions: Drug: eszopiclone; Drug: eszopiclone; Drug: Placebo
Sponsor: Sepracor, Inc.
Recruiting - verified May 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Recruiting - verified August 2010
Condition: Meningococcal Meningitis
Interventions: Other: Group I; Other: Group II; Other: Group III; Other: Group IV; Other: Group V
Sponsors: Novartis; Novartis Vaccines
Recruiting - verified August 2010
Condition: Gastroesophageal Reflux
Intervention: Drug: Rabeprazole sodium
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Eisai Inc.
Recruiting - verified August 2010
Condition: Aspergillosis
Intervention: Other: No Intervention
Sponsor: Merck
Recruiting - verified August 2010
Conditions: Overactive Bladder; Neurogenic Detrusor Overactivity
Intervention: Drug: Fesoterodine
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Hyperbilirubinemia, Neonatal
Interventions: Drug: stannsoporfin; Other: Saline
Sponsor: InfaCare Pharmaceuticals Corporation
Recruiting - verified August 2010
Condition: Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: CT-322; Drug: Bevacizumab; Drug: Bevacizumab placebo (ie saline solution)
Sponsor: Bristol-Myers Squibb
Recruiting - verified April 2010
Condition: Gout
Interventions: Biological: Rilonacept; Other: Placebo
Sponsor: Regeneron Pharmaceuticals
Recruiting - verified August 2010
Condition: Major Depressive Disorder
Interventions: Drug: duloxetine; Drug: Placebo; Drug: fluoxetine
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Adrenocortical Carcinoma
Intervention: Drug: R-(-)-gossypol acetic acid
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2010
Conditions: Gastroparesis; Diabetic Gastroparesis; Diabetes; Diabetes Mellitus; Delayed Gastric Emptying
Interventions: Drug: metoclopramide; Drug: Placebo
Sponsor: Evoke Pharma
Recruiting - verified August 2010
Condition: Multiple Myeloma
Intervention: Drug: lenalidomide
Sponsors: Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; Celgene Corporation
Recruiting - verified August 2010
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: ABI-007/Gemcitabine; Drug: Gemcitabine
Sponsor: Abraxis BioScience Inc.
Recruiting - verified June 2010
Condition: Bipolar Depression
Interventions: Drug: Olanzapine Fluoxetine Combination; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Conditions: Anemia; Leukemia; Myelodysplastic Syndromes
Interventions: Biological: epoetin alfa; Drug: lenalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Alzheimer's Disease
Interventions: Drug: ST101; Drug: ST101; Drug: ST101; Drug: Placebo
Sponsor: Sonexa Therapeutics, Inc.
Recruiting - verified August 2010
Conditions: Cardiac Surgery; Atrial Fibrillation; Post-Operative Delirium
Interventions: Drug: Lidocaine; Drug: Lidocaine; Other: Placebo
Sponsor: Outcomes Research Consortium
Recruiting - verified August 2010
Condition: Leukemia
Interventions: Drug: cytarabine; Drug: idarubicin; Drug: pravastatin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Haemophilia A
Interventions: Drug: recombinant factor VIII (N8); Procedure: Blood drawn for laboratory testing
Sponsor: Novo Nordisk
Recruiting - verified September 2010
Condition: Phenylketonuria
Intervention: Drug: sapropterin dihydrochloride
Sponsor: BioMarin Pharmaceutical
Recruiting - verified August 2010
Condition: Carcinoma, Renal Cell
Interventions: Drug: axitinib; Drug: axitinib; Drug: axitinib
Sponsor: Pfizer
Recruiting - verified August 2010
Conditions: Abdominal Aortic Aneurysms; Iliac Aneurysms; Aorto-iliac Aneurysms
Intervention: Device: Zenith(R) Low Profile AAA Endovascular Graft
Sponsor: Cook
Recruiting - verified September 2010
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Cicletanine HC1 or placebo
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer; Duke University
Recruiting - verified April 2010
Conditions: Adrenocortical Carcinoma; Kidney Cancer; Liver Cancer; Neuroblastoma; Retinoblastoma; Sarcoma
Interventions: Biological: cixutumumab; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Parkinson Disease
Interventions: Drug: Placebo; Drug: inosine; Drug: inosine
Sponsors: The Parkinson Study Group; Massachusetts General Hospital; Harvard School of Public Health; University of Rochester; Michael J. Fox Foundation for Parkinson's Research
Recruiting - verified August 2010
Condition: Lung Cancer
Interventions: Biological: aflibercept; Drug: topotecan hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: capecitabine; Drug: lapatinib; Drug: trastuzumab-MCC-DM1
Sponsors: Genentech; Roche Pharma AG
Recruiting - verified August 2010
Condition: Liver Cancer
Interventions: Drug: Brivanib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified August 2010
Condition: HIV-1
Interventions: Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: HIV-1
Interventions: Drug: UK-453,061 Dose 1; Drug: UK-453,061 Dose 2; Drug: Etravirine
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Traumatic Brain Injury
Intervention: Drug: Progesterone
Sponsors: Emory University; Henry Ford Hospital; Medical College of Wisconsin; New York Presbyterian Hospital; Oregon Health and Science University; Stanford University; Temple University; University of Arizona; University of California; University of Cincinnati; University of Kentucky; University of Maryland; University of Minnesota - Clinical and Translational Science Institute; University of Texas; University of Pennsylvania; Virginia Commonwealth University; Wayne State University
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Degenerative Joint Disease; Osteoarthritis; Rheumatoid Arthritis; Traumatic Arthritis
Intervention: Device: 3DKnee™ System
Sponsor: Encore Medical, L.P.
Recruiting - verified August 2010
Condition: Cytomegalovirus Infections
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2009
Condition: Metastatic Colorectal Cancer
Interventions: Biological: AMG 479; Other: Placebo; Other: FOLFIRI; Biological: AMG 655
Sponsor: Amgen
Recruiting - verified September 2010
Conditions: Chemotherapeutic Agent Toxicity; Endometrial Cancer; Fallopian Tube Cancer; Gastrointestinal Complications; Neurotoxicity; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: cisplatin; Drug: paclitaxel; Procedure: assessment of therapy complications
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Pulmonary Hypertension
Interventions: Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Recruiting - verified August 2010
Conditions: Acute Coronary Syndrome; Myocardial Infarction; Myocardial Ischemia; Unstable Angina
Interventions: Drug: Placebo; Drug: Rivaroxaban 5 mg; Drug: Rivaroxaban 2.5 mg
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Bayer
Recruiting - verified August 2010
Condition: Pulmonary Hypertension
Interventions: Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Recruiting - verified August 2010
Condition: Status Epilepticus
Interventions: Other: Intramuscular route of active treatment; Other: Intravenous route of active treatment
Sponsors: University of Michigan; Medical University of South Carolina; University of California, San Francisco; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified June 2010
Condition: Vertebral Body Compression Fractures (VCFs)
Intervention: Device: Kyphon® Curette
Sponsor: Medtronic Spine LLC
Recruiting - verified August 2010
Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: BIBF1120; Drug: Folic Acid; Drug: Folic Acid; Drug: BIBF1120 placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Condition: Arthritis, Juvenile Rheumatoid
Interventions: Drug: Celecoxib; Drug: Naproxen
Sponsor: Pfizer
Recruiting - verified September 2010
Condition: Idiopathic Restless Legs Syndrome
Interventions: Drug: placebo and pregabalin; Drug: pramipexol; Drug: pramipexol; Drug: Pregabalin; Drug: pramipexol; Drug: pramipexol
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Metastatic Non-small Cell Lung Cancer
Interventions: Drug: CS7017 tablets; Drug: Paclitaxel; Drug: Carboplatin
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified August 2010
Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Metastatic Colorectal Cancer
Interventions: Biological: cetuximab; Drug: 5-FU; Drug: oxaliplatin; Drug: leucovorin
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); Bristol-Myers Squibb
Recruiting - verified August 2010
Condition: Cystic Fibrosis
Interventions: Drug: Ataluren (PTC124); Drug: Placebo
Sponsors: PTC Therapeutics; Genzyme; Cystic Fibrosis Foundation
Recruiting - verified August 2010
Conditions: Nicotine Dependence; Alcohol Dependence
Interventions: Drug: Topiramate; Drug: Placebo
Sponsor: Department of Veterans Affairs
Recruiting - verified August 2010
Conditions: Delayed Graft Function; Kidney Transplant
Interventions: Drug: I5NP; Drug: Saline
Sponsor: Quark Pharmaceuticals
Recruiting - verified September 2010
Condition: Shoulder Surgery
Interventions: Drug: Ropivacaine; Drug: Bupivacaine; Drug: Dexamethasone; Drug: Placebo
Sponsor: Outcomes Research Consortium
Recruiting - verified August 2010
Condition: Chronic Plaque Psoriasis
Intervention: Biological: HUMIRA® (adalimumab)
Sponsor: Abbott
Recruiting - verified August 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: pemetrexed disodium; Genetic: gene expression analysis; Genetic: polymorphism analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Procedure: quality-of-life assessment
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Solid Tumors
Intervention: Drug: Sunitinib
Sponsor: Pfizer
Recruiting - verified August 2010
Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension; ETRA; PAH
Interventions: Drug: Sitaxsentan; Drug: Sitaxsentan and Sildenafil
Sponsor: Pfizer
Recruiting - verified September 2010
Condition: Leukemia
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: methylprednisolone; Drug: prednisone; Drug: sirolimus; Drug: tacrolimus; Drug: vincristine sulfate; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Other: active surveillance
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Crohn's Disease
Intervention:
Sponsors: Emory University; Crohn's and Colitis Foundation
Recruiting - verified May 2010
Condition: Human Immunodeficiency Virus (HIV)
Intervention: Drug: Maraviroc
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Breast Cancer
Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Ixabepilone (Ixempra); Drug: Paclitaxel (Taxol)
Sponsors: Sarah Cannon Research Institute; Bristol-Myers Squibb
Recruiting - verified August 2010
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RAD001; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol; Drug: Placebo
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified August 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol; Drug: placebo tablets
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified August 2010
Conditions: Colon Cancer; Colorectal Cancer; Rectal Cancer; Metastatic Colorectal Cancer
Interventions: Drug: Panitumumab; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsor: Amgen
Recruiting - verified September 2010
Conditions: GERD; Gastroesophageal Reflux Disease
Interventions: Drug: rabeprazole; Drug: rabeprazole
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Eisai Inc.
Recruiting - verified August 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: ixabepilone; Drug: paclitaxel; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Pulmonary Fibrosis
Intervention: Drug: CNTO 888
Sponsor: Centocor, Inc.
Recruiting - verified August 2010
Condition: Crohn's Disease
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified September 2010
Condition: Ulcerative Colitis
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified September 2010
Condition: Juvenile Idiopathic Arthritis
Interventions: Drug: adalimumab; Drug: Methotrexate
Sponsor: Abbott
Recruiting - verified July 2010
Condition: Migraine
Interventions: Drug: DR-105; Other: Placebo
Sponsor: Duramed Research
Recruiting - verified August 2010
Condition: Adrenocortical Carcinoma
Interventions: Biological: cixutumumab; Drug: mitotane
Sponsors: University of Chicago; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity
Interventions: Dietary Supplement: acetyl-L-carnitine hydrochloride; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: B-cell Chronic Lymphocytic Leukemia
Interventions: Drug: Lenalidomide; Drug: Placebo
Sponsor: Celgene Corporation
Recruiting - verified August 2010
Condition: Chronic Migraine
Interventions: Drug: propranolol LA; Drug: topiramate; Drug: placebo
Sponsors: The EMMES Corporation; National Institute of Neurological Disorders and Stroke (NINDS); Ortho-McNeil Janssen Scientific Affairs, LLC; CRC Operations Center
Recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Recurrent Prostate Cancer
Intervention: Device: High Intensity Focused Ultrasound
Sponsor: USHIFU, LLC
Recruiting - verified August 2010
Condition: Multiple Myeloma
Interventions: Drug: vorinostat (an HDAC inhibitor); Drug: bortezomib
Sponsor: Merck
Recruiting - verified August 2010
Condition: Asthma
Interventions: Drug: tiotropium 5mcg/day; Drug: tiotropium 5mcg/day
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified August 2010
Condition: Asthma
Interventions: Drug: tiotropium 5mcg/day; Drug: tiotropium 5mcg/day
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified August 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: lapatinib ditosylate; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Macular Edema; Retinal Vein Occlusion
Interventions: Drug: Fluocinolone Acetonide; Drug: Fluocinolone Acetonide
Sponsor: Alimera Sciences
Recruiting - verified August 2010
Conditions: Cancer; Carcinoma; Fallopian Tube Cancer; Gynecological Malignancies; Metastases; Oncology; Ovarian Cancer; Solid Tumors; Tumors
Interventions: Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin; Drug: A3: AMG 386 15mg/kg + Liposomal doxorubicin; Drug: B1: AMG 386 10 mg/kg + Topotecan; Drug: B3: AMG 386 15mg/kg + Topotecan
Sponsor: Amgen
Recruiting - verified August 2010
Condition: Lymphoma
Interventions: Biological: rituximab; Biological: tositumomab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Radiation: iodine I 131 tositumomab
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Malignant Mesothelioma
Intervention: Drug: everolimus
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Melanoma
Interventions: Biological: OncoVEXGM-CSF; Biological: GM-CSF
Sponsor: BioVex Limited
Recruiting - verified August 2010
Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: ambrisentan or sugar pill
Sponsor: Gilead Sciences
Recruiting - verified August 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin; Biological: Bevacizumab; Biological: Bevacizumab
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Conditions: Candidemia; Candidiasis
Interventions: Drug: anidulafungin; Drug: fluconazole
Sponsor: Pfizer
Recruiting - verified August 2010
Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: panitumumab; Drug: cisplatin; Drug: docetaxel; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Optic Neuropathy, Ischemic
Intervention:
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Multiple Sclerosis
Interventions: Drug: Duloxetine HCI; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified September 2010
Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Ovarian Cancer
Intervention: Biological: bevacizumab
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: GERD
Intervention: Drug: Rabeprazole sodium
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Eisai Inc.
Recruiting - verified August 2010
Conditions: Barrett's Esophagus With or Without Dysplasia; Squamous Dysplasia of the Esophagus; Esophageal Cancer (Any Stage)
Intervention:
Sponsor: CSA Medical, Inc.
Recruiting - verified August 2010
Condition: Prostatic Neoplasms
Interventions: Drug: placebo + docetaxel/prednisone; Drug: dasatinib + docetaxel/prednisone
Sponsor: Bristol-Myers Squibb
Recruiting - verified April 2010
Condition: Carotid Artery Disease
Interventions: Device: Carotid WALLSTENT Monorail Endoprosthesis; Device: FilterWire EZ™ System™
Sponsor: Boston Scientific Corporation
Recruiting - verified August 2010
Conditions: Fibrosis; Kidney Failure; Renal Insufficiency
Intervention: Procedure: Lab sample drawn for serum chemistry at baseline visit
Sponsor: Bayer
Recruiting - verified August 2010
Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab); Drug: 0.9% Saline
Sponsor: Morphotek
Recruiting - verified August 2010
Conditions: Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders; Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: survey administration; Procedure: assessment of therapy complications; Procedure: long-term screening; Procedure: study of high risk factors
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Diabetes Mellitus
Interventions: Drug: Exubera; Other: Randomized diabetes therapy
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Hypoparathyroidism
Interventions: Drug: Placebo; Drug: NPSP558
Sponsor: NPS Pharmaceuticals
Recruiting - verified August 2010
Condition: Endometrial Cancer
Interventions: Drug: megestrol acetate; Drug: tamoxifen citrate; Drug: temsirolimus
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Irritable Bowel Syndrome With Constipation; Chronic Constipation
Intervention: Drug: Linaclotide
Sponsors: Ironwood Pharmaceuticals, Inc.; Forest Laboratories
Recruiting - verified August 2010
Condition: Colorectal Cancer
Interventions: Procedure: therapeutic conventional surgery; Procedure: therapeutic laparoscopic surgery
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Neoplasms; Lymphoma; Multiple Myeloma
Interventions: Drug: SCH 900105; Drug: SCH 900105; Drug: SCH 900105; Drug: Erlotinib
Sponsors: Schering-Plough; AVEO Pharmaceuticals, Inc.
Recruiting - verified August 2010
Condition: Hysterectomy
Interventions: Drug: Lidocaine; Drug: Ketamine; Drug: Lidocaine and Ketamine; Other: placebo
Sponsor: Outcomes Research Consortium
Recruiting - verified August 2010
Conditions: Chronic Myeloproliferative Disorders; Fatigue; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Dietary Supplement: American ginseng; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Cystic Fibrosis
Interventions: Drug: 7% Hypertonic Saline (HS); Drug: 0.9% Isotonic Saline (IS)
Sponsors: CF Therapeutics Development Network Coordinating Center; Cystic Fibrosis Foundation; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Talactoferrin; Drug: Placebo
Sponsor: Agennix
Recruiting - verified August 2010
Conditions: Pain; Nausea; Vomiting; Wound Infection
Interventions: Drug: propofol, or Etomidate, fentanyl; Drug: lidocaine; Drug: placebo
Sponsor: Outcomes Research Consortium
Recruiting - verified August 2010
Conditions: Systemic Sclerosis; Pulmonary Arterial Hypertension; Pulmonary Hypertension
Intervention:
Sponsor: Actelion
Recruiting - verified August 2010
Condition: Melanoma (Skin)
Intervention: Drug: dasatinib
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Liver Diseases
Intervention:
Sponsor: Outcomes Research Consortium
Recruiting - verified August 2010
Condition: Fabry Disease
Interventions: Biological: agalsidase beta; Biological: agalsidase beta
Sponsor: Genzyme
Recruiting - verified July 2010
Condition: Acute Coronary Syndrome
Interventions: Drug: Clopidogrel; Drug: Prasugrel; Drug: Commercially-available Aspirin
Sponsors: Eli Lilly and Company; Daiichi Sankyo Co., Ltd.; Duke University
Recruiting - verified August 2010
Conditions: Malignant Pleural Mesothelioma; MPM; Solid Tumors
Interventions: Drug: pemetrexed, cisplatin and CBP501; Drug: pemetrexed and cisplatin
Sponsor: CanBas Co. Ltd.
Recruiting - verified August 2010
Condition: Lung Cancer
Interventions: Drug: pemetrexed disodium; Drug: sunitinib malate
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: Dasatinib + Letrozole; Drug: Letrozole
Sponsors: Bristol-Myers Squibb; US Oncology Research
Recruiting - verified September 2010
Condition: Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Recruiting - verified August 2010
Condition: Cervical Cancer
Interventions: Drug: cisplatin; Drug: pemetrexed disodium
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Retinoblastoma
Interventions: Genetic: DNA ploidy analysis; Genetic: DNA stability analysis; Genetic: Southern blotting; Genetic: genetic linkage analysis; Genetic: loss of heterozygosity analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: evaluation of cancer risk factors; Procedure: mutation carrier screening
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Arthritis, Juvenile Rheumatoid
Interventions: Drug: Celecoxib; Drug: nsNSAIDs
Sponsor: Pfizer
Recruiting - verified September 2010
Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Drug: capecitabine; Drug: oxaliplatin; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Procedure: neoadjuvant therapy; Procedure: therapeutic surgical procedure; Radiation: radiation therapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Breast Cancer
Interventions: Biological: cixutumumab; Drug: capecitabine; Drug: lapatinib ditosylate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI); Southwest Oncology Group
Recruiting - verified September 2010
Condition: Thromboembolism
Interventions: Drug: Dabigatran etexilate; Drug: Warfarin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: cilengitide
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736); Drug: Sorafenib
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Prostatic Neoplasms
Interventions: Drug: Prednisone; Drug: sunitinib; Drug: Placebo; Drug: Prednisone
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Multiple Sclerosis
Interventions: Drug: Teriflunomide (HMR1726); Drug: Placebo
Sponsor: Sanofi-Aventis
Recruiting - verified August 2010
Conditions: Kidney Cancer; Leukemia; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: dactinomycin; Drug: vincristine sulfate; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Leukemia
Interventions: Drug: SC-PEG E. coli L-asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Uterine Neoplasms; Endometrial Cancer; Vaginal Cancer; Vulvar Cancer; Cervical Cancer; Lung Cancer; Carcinoid Tumor of Lung; Sarcoma of Lung; Mesothelioma; Colorectal Cancer
Intervention:
Sponsor: Precision Therapeutics
Recruiting - verified August 2010
Condition: Leukemia
Interventions: Drug: bortezomib; Drug: cytarabine; Drug: etoposide phosphate; Drug: idarubicin
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
All Locations ... United States » ... Ohio 